These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21261708)

  • 1. Much ado about Nutlin.
    Teoh NC
    J Gastroenterol Hepatol; 2011 Feb; 26(2):213-5. PubMed ID: 21261708
    [No Abstract]   [Full Text] [Related]  

  • 2. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
    Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
    Cipriano R; Patton JT; Mayo LD; Jackson MW
    Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF; Kua N; Kaldis P; Lane DP
    Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival.
    Zhang Y; Shu L; Chen X
    J Biol Chem; 2008 Nov; 283(45):30689-98. PubMed ID: 18779328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
    Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
    Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
    Bauer S; Mühlenberg T; Leahy M; Hoiczyk M; Gauler T; Schuler M; Looijenga L
    Eur Urol; 2010 Apr; 57(4):679-87. PubMed ID: 19560254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 downregulates p53 phosphorylation on serine392 and induces apoptosis in hepatocellular carcinoma cells.
    Shi X; Liu J; Ren L; Mao N; Tan F; Ding N; Yang J; Li M
    BMB Rep; 2014 Apr; 47(4):221-6. PubMed ID: 24286312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.